| 08/02/23 | 07:00:05 | 8 Feb 2023 | | Issue of Equity |
| 01/02/23 | 07:00:09 | 1 Feb 2023 | | Dr Jean-Michel Cosséry appointed as Chairman |
| 25/01/23 | 07:00:04 | 25 Jan 2023 | | Interim Results |
| 18/01/23 | 07:00:06 | 18 Jan 2023 | | Notice of Interim Results |
| 06/12/22 | 16:40:39 | 6 Dec 2022 | | Second Price Monitoring Extn |
| 06/12/22 | 16:35:30 | 6 Dec 2022 | | Price Monitoring Extension |
| 21/11/22 | 15:18:34 | 21 Nov 2022 | | Result of Annual General Meeting |
| 07/11/22 | 07:00:06 | 7 Nov 2022 | | Licenses Vaccitech technology to advance Modi-2 |
| 31/10/22 | 07:00:07 | 31 Oct 2022 | | First patient dosed in expansion phase of ModiFY |
| 28/10/22 | 15:00:05 | 28 Oct 2022 | | Notice of AGM |
| 28/10/22 | 07:00:06 | 28 Oct 2022 | | Results for the year ended 30 April 2022 |
| 26/10/22 | 07:00:06 | 26 Oct 2022 | | Directorate Changes |
| 25/10/22 | 16:42:19 | 25 Oct 2022 | | Second Price Monitoring Extn |
| 25/10/22 | 16:37:02 | 25 Oct 2022 | | Price Monitoring Extension |
| 25/10/22 | 14:05:49 | 25 Oct 2022 | | Second Price Monitoring Extn |
| 25/10/22 | 14:00:35 | 25 Oct 2022 | | Price Monitoring Extension |
| 25/10/22 | 11:05:23 | 25 Oct 2022 | | Second Price Monitoring Extn |
| 25/10/22 | 11:00:23 | 25 Oct 2022 | | Price Monitoring Extension |
| 25/10/22 | 07:00:04 | 25 Oct 2022 | | Signs Commercial License Agreement with Genmab |
| 13/10/22 | 07:00:05 | 13 Oct 2022 | | Change of Nominated Adviser |
| 28/09/22 | 12:31:39 | 28 Sept 2022 | | Holding(s) in Company |
| 23/09/22 | 07:00:07 | 23 Sept 2022 | | Preclinical data at the EuroMAbNet Annual Meeting |
| 06/09/22 | 12:54:50 | 6 Sept 2022 | | Change of Registered Office |
| 16/08/22 | 14:00:06 | 16 Aug 2022 | | First patient dosed in Cohort 2 of the ModiFY |
| 23/06/22 | 07:00:05 | 23 Jun 2022 | | Scancell to produce TCB antibodies |
| 15/06/22 | 14:06:15 | 15 Jun 2022 | | Second Price Monitoring Extn |
| 15/06/22 | 14:00:42 | 15 Jun 2022 | | Price Monitoring Extension |
| 15/06/22 | 07:00:02 | 15 Jun 2022 | | Phase 2 SCOPE trial of SCIB1 vaccine expanded |
| 13/06/22 | 07:00:06 | 13 Jun 2022 | | First patient dosed in Modi-1 Phase 1 trial |
| 12/04/22 | 15:47:24 | 12 Apr 2022 | | Change of Registered Holder of Shares |
| 11/04/22 | 14:06:00 | 11 Apr 2022 | | Second Price Monitoring Extn |
| 11/04/22 | 14:00:42 | 11 Apr 2022 | | Price Monitoring Extension |
| 11/04/22 | 11:05:33 | 11 Apr 2022 | | Second Price Monitoring Extn |
| 11/04/22 | 11:00:17 | 11 Apr 2022 | | Price Monitoring Extension |
| 11/04/22 | 07:00:07 | 11 Apr 2022 | | Modi-1 Phase 1/2 trial open for recruitment |
| 29/03/22 | 07:00:09 | 29 Mar 2022 | | Update on COVIDITY clinical trial |
| 17/03/22 | 07:00:04 | 17 Mar 2022 | | Scancell progresses its new anti-glycan mAb |
| 03/03/22 | 09:55:34 | 3 Mar 2022 | | Director Dealing |
| 31/01/22 | 07:00:08 | 31 Jan 2022 | | Update on COVIDITY Phase 1 clinical trial |
| 26/01/22 | 07:00:06 | 26 Jan 2022 | | Interim Results for the 6 months ended 31 Oct 2021 |
| 22/12/21 | 09:45:06 | 22 Dec 2021 | | Notice of Interim Results |
| 13/12/21 | 16:41:48 | 13 Dec 2021 | | Second Price Monitoring Extn |
| 13/12/21 | 16:36:49 | 13 Dec 2021 | | Price Monitoring Extension |
| 23/11/21 | 15:58:17 | 23 Nov 2021 | | Result of AGM |
| 19/11/21 | 07:00:03 | 19 Nov 2021 | | First patient dosed in SCIB1 Phase 2 trial |
| 03/11/21 | 10:28:23 | 3 Nov 2021 | | Director Dealing |
| 02/11/21 | 10:07:03 | 2 Nov 2021 | | Director Dealing |
| 01/11/21 | 09:50:21 | 1 Nov 2021 | | Notice of Annual General Meeting |
| 29/10/21 | 07:00:06 | 29 Oct 2021 | | Results for the year ended 30 April 2021 |
| 28/10/21 | 11:23:15 | 28 Oct 2021 | | Extension of CLN Redemption Dates |
